Interestingly, since the small inhibitor of Rho/myocardin-related transcription factor (MRTF)/serum response factor (SRF)-mediated gene transcription CCG-203971 was able to inhibit CTGF, α-SMA, and collagen synthesis in both SSc fibroblasts and experimental scleroderma [196], novel inhibitors of the Rho/MRTF/SRF transcription pathway are now under investigation as potential antifibrotic drugs for SSc treatment [197,198]. This evidence concerns the gene CCN2 and systemic sclerosis.